Drug intelligence / Profile preview

JYP0035

Development stage: Phase 3
Lead developer: Jiayue
Modality: Small Molecules
Administration: Oral

Overview

JYP0035 is an investigational small molecule drug currently in Phase 1 clinical trials for the treatment of advanced solid tumors. The drug is being developed as an oral capsule and is undergoing evaluation for its safety, tolerability, and pharmacokinetic properties in patients with various advanced solid malignancies. The precise mechanism of action has not been disclosed or remains unknown at this stage. Clinical studies are being conducted primarily in China by Chengdu Joyo Pharma Co., Ltd., with a focus on oncology indications.

Beyond the preview

Go deeper on JYP0035.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JYP0035.

Explore the full profile